Arthur S. Kirsch – Chairman
Arthur S. Kirsch is Chairman of the Board of Aralez Pharmaceuticals Inc. and served in this role with the company’s predecessor, POZEN Inc., since June 1, 2015 and on the Board since May 2004. He is chairman of the audit committee and a member of the compensation and governance/nominating committees. Mr. Kirsch has over 30 years of experience working in the equity capital markets and has extensive knowledge of the healthcare and life sciences field. Since 2005 he has been a Senior Advisor with GCA Savvian, LLC (formerly Perseus Group, LLC), an investment bank. Prior to GCA Savvian he was a founding member and managing director of Vector Securities, LLC, an investment and merchant banking firm.
Mr. Kirsch has also held senior leadership positions at Prudential Vector Healthcare Group, a unit of Prudential Securities, Inc., and at Vector Securities International, Inc. Before joining Vector in 1995, he was president and chief executive officer of NatWest Securities U.S. and director of the Global Equity Division of Drexel Burnham Lambert. Mr. Kirsch also serves on the Board of Directors for Immunomedics.
Mr. Adams is Chief Executive Officer and a Director of Aralez Pharmaceuticals Inc. and served in this role with the company’s predecessor, POZEN Inc., since June 1, 2015. Prior to joining the company, Mr. Adams served as Chief Executive Officer and President of Auxilium Pharmaceuticals, Inc. from December 2011 until its acquisition by Endo International plc in January 2015 for $2.6 billion. Under his leadership, Auxilium transformed into a men’s healthcare company and broadened its portfolio from two to twelve through the strategic corporate acquisition of Actient Holding LLC and product in-licensing. Prior to joining Auxilium, Mr. Adams served as Chairman and Chief Executive Officer of Neurologix, Inc., a company focused on development of multiple innovative gene therapy development programs. Before Neurologix, Mr. Adams served as President and Chief Executive Officer of Inspire Pharmaceuticals, Inc., where he oversaw the commercialization and development of prescription pharmaceutical products and led the company through a strategic acquisition by global pharmaceutical leader Merck & Co., Inc. in May 2011 for $430 million. Prior to Inspire, Mr. Adams served as President and Chief Executive Officer of Sepracor Inc. from December 2006 until its acquisition by Dainippon Sumitomo Pharma Co. in February 2010 for $2.6 billion. Under his leadership, Sepracor conducted multiple strategic corporate development activities, including the in-licensing of seven products and out-licensing deals with two major pharmaceutical companies, prior to its acquisition by Dainippon Sumitomo Pharma Co.
Prior to joining Sepracor, Mr. Adams was President and Chief Executive Officer of Kos Pharmaceuticals, Inc. from 2002 until the acquisition of the company by Abbott Laboratories in December 2006 for $3.7 billion. During his tenure he led the transformation of Kos into a fully integrated and profitable pharmaceutical company with annual revenues approaching $1 billion. During his 30 years of experience, Mr. Adams also held general management and senior marketing positions at ICI (now part of AstraZeneca), SmithKline Beecham and Novartis. He has extensive international and national experience and has been instrumental in launching major global brands in addition to driving successful corporate development activities encapsulating financing, product and company acquisitions, in-licensing and company M&A activities.
Mr. Adams graduated from the Royal Institute of Chemistry at Salford University in the U.K. Mr. Adams serves as Chairman of the Board of AcelRx Pharmaceuticals and recently served as a director of Amylin Pharmaceuticals.
Kenneth B. Lee, Jr.
Kenneth B. Lee, Jr. serves as a member of the Board of Directors of Aralez Pharmaceuticals Inc. and served in this role with the company’s predecessor, POZEN Inc., since December 2002. He is chairman of the compensation committee and a member of the audit committee. Mr. Lee is a managing member of Hatteras Venture Partners, a venture capital fund focusing on life sciences companies. Mr. Lee spent 29 years with Ernst & Young, primarily in the Palo Alto Office. He ran the Firms Life Sciences Practice in the US and was Co-Chair of the International Life Sciences Practice. He is a co-founder of the National Conference on Biotechnology Ventures and co-authored the Ernst & Young Life Sciences Annual Report for many years. and serves as a director of CV Therapeutics and Abgenix and Inspire Pharmaceuticals. Mr. Lee also advised biotechnology and pharmaceutical companies throughout the world on a wide range of financial and strategic planning issues. After retiring from Ernst & Young, he served on the boards of Abgenix, CV Therapeutics, Inspire Pharmaceuticals, Maxygen and OSI Pharmaceuticals. Mr. Lee currently serves on the boards of Aralez and Biocryst Pharmaceuticals.
Mr. Lee received a Bachelor of Arts degree from Lenoir-Rhyne College and an MBA from the University of North Carolina at Chapel Hill.
F. Martin Thrasher
Mr. Thrasher serves as a member of the Board of Directors of Aralez Pharmaceuticals Inc. since February 5, 2016. Mr. Thrasher is a seasoned international executive. After graduating from the Richard Ivey School of Business in London ON. Thrasher spent over 30 years working around the globe for companies such as General Foods, McCormick & Co, Campbell Soup Co. and ConAgra Foods Inc. Mr. Thrasher lived and worked in Canada, Australia, Belgium and the USA. His responsibilities with Campbell Soup Co. included positions as President, International Grocery and President, North America Grocery. At ConAgra Foods Inc., he was President of the Retail Products Co, a $9 billion business with over 30,000 employees. Currently, Mr. Thrasher is President of FMT Consulting, a boutique advisory and consulting firm. Mr. Thrasher was chosen as a Director in light of his significant international business experience with Fortune 500 companies.